Hims & Hers now faces a potential peptide opportunity with a changed enforcement outlook but no new clinical evidence. Health and Human Services Secretary Robert F. Kennedy Jr. has introduced a policy under which HHS would refrain from enforcement against specified providers compounding six unapproved peptides. For companies weighing entry, the immediate question is whether that policy offers enough certainty to justify investment.
Access Policy Is Moving Faster Than Clinical Development
Kennedy’s change in approach brings the peptide debate into a more consequential phase. His earlier effort sought to remove FDA restrictions. The new approach instead uses enforcement discretion to expand access through state-licensed pharmacies, federal facilities and licensed physicians.
That distinction should guide commercial decisions. A decision to refrain from enforcement does not establish safety or effectiveness. These peptides lack clinical trials testing those outcomes, and dangerous adverse effects have been reported. FDA reviewers recommended against expanded use during the July advisory proceedings, even as outside advisers narrowly supported lifting restrictions on six products. The immediate development is therefore an access shift rather than a clinical-development milestone. Providers may have more room to offer the compounds without the evidence base having advanced alongside that opportunity.
HHS presents the policy as supporting patient autonomy. An HHS official also argued that licensed domestic compounders could offer a more controlled route than the black and gray markets already serving demand. That is the strongest practical argument for the change: move existing use into identifiable healthcare channels. It also sets a demanding test. If the policy is intended to improve control over supply and treatment, adoption decisions should turn on how that control will work.
Enforcement Discretion Creates a Different Market Signal
The six compounds span several proposed treatment areas. The advisory panel supported KPV and TB-500, promoted for wound treatment; BPC-157, promoted for ulcerative colitis; MOTS-c, for weight reduction; Semax, for migraine treatment; and Epitalon, for insomnia. Those proposed uses should not be confused with demonstrated clinical benefits.
The panel opposed emideltide, considered for opioid withdrawal and sleep disorders. Kennedy’s policy excludes it. That boundary gives the measure a defined scope, but it does little to resolve the broader evidence question.
For biopharma management, the timing is significant because a commercial opening may emerge before conventional development has supplied the basis for clinical confidence. Companies accustomed to treating regulatory progress as a proxy for reduced product risk will need a more precise reading here. Enforcement exposure and therapeutic uncertainty are separate issues. HHS is accepting public comments for two weeks. That gives prospective participants a near-term reason to examine the policy’s scope and submit operational concerns. It also argues against treating the notice as a settled foundation for a large rollout.
Opposition reinforces that uncertainty. Robert Steinbrook, the health research group director at Public Citizen, accused Kennedy of weakening the FDA and, in doing so, putting public health at risk. Fred Mills, chief policy officer for Americans for Safe & Effective Medicines, argued that an access route would leave unresolved concerns about untested compounds, ingredient quality and misleading promotion. Without adequate oversight, Mills warned, the harms associated with large-scale compounding could also worsen. Before providers can make a credible case for adoption, they would need to answer those objections.
Licensed Supply Is Only the First Adoption Step
Moving patients toward licensed providers could make supply more visible. More dependable care, though, will depend on the standards those providers apply.
A telemedicine company or pharmacy weighing participation should review the following:
- Clinical boundaries: Which patients could reasonably be considered, and what uncertainty must be explained before treatment?
- Supplier controls: What evidence would support confidence in ingredient identity and preparation quality?
- Claims review: How would marketing keep proposed uses distinct from benefits not established in clinical trials?
- Safety oversight: How would providers record and review adverse events? How would those findings inform a reconsideration of prescribing?
These are proposed safeguards for management, not requirements established by the notice. They give teams a concrete basis for deciding whether to participate, beyond the broad appeal of peptide demand.
Even through a licensed channel, providers need a care model they can defend. That would mean explaining why they choose a compound and how they select patients. Providers would also need to set out their response when outcomes are uncertain or adverse effects emerge. Commercial teams should assess launch readiness against those questions as well as the enforcement policy. For developers pursuing evidence-backed therapies, this also raises a competitive planning issue. An access route for unapproved compounds could bring alternatives into the market before comparable clinical evidence exists. Strategy should account for that possibility without assuming that easier availability will translate into durable adoption.
The Investment Case Remains Conditional
Leerink Partners analyst Michael Cherny described the policy as a cautious signal rather than sufficient clearance for full commercial participation. His earlier estimate placed the annual peptide telehealth opportunity between $1.1 billion and $2.2 billion. That remains a forecast, not evidence of an established market.
Cherny judged that the measure could bring the opportunity forward by at least several months, while leaving substantial uncertainty for Hims & Hers. The distinction is commercially useful: an earlier opening can justify preparation without justifying immediate scale. Management teams can use the comment period to clarify exposure, assess prospective suppliers and define clinical governance. Investment should then follow the answers. The strategic advantage may belong to providers able to demonstrate disciplined prescribing and credible oversight, rather than those quickest to add peptides to a product menu.
Kennedy’s policy has made access a live operating decision. The clinical evidence needed to make that decision easy is still missing. Launch plans should treat access and evidence separately, with explicit conditions for proceeding, pausing or withdrawing an offering.
